Unit Price: 2.00 ( x 150: 300.35)
Package unit 10 tabs strip
Origin Country: Bangladesh
Commercial Pack 150
Price per pack 300.35
Package unit 10 tabs strip
Price per unit 2.00

Classes

Gastrointestinal Agent , Antiulcerants , H2 Blocker / Histamine-2 Receptor Antagonist

Ranitidine

Ranitidine is a histamine-2 blocker, which decreases the amount of acid created by the stomach. Ranitidine is available as tablets, effervescent tablets and syrup.

Ranitidine is indicated for the following conditions-

  • duodenal ulcer
  • Maintenance therapy for duodenal ulcer
  • Zollinger-Ellison syndrome and systemic mastocytosis
  • gastric ulcer
  • gastro-esophagal reflux disease
  • erosive esophagitis

 

  • Active Duodenal Ulcer: The current recommended adult oral dosage of Ranitidine for duodenal ulcer is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice daily. An alternative dosage of 300 mg or 20 mL of syrup (4 teaspoonfuls of syrup equivalent to 300 mg of ranitidine) once daily after the evening meal or at bedtime can be used for patients in whom dosing convenience is important. The advantages of one treatment regimen compared to the other in a particular patient population have yet to be demonstrated (see Clinical Trials: Active Duodenal Ulcer). Smaller doses have been shown to be equally effective in inhibiting gastric acid secretion in US studies, and several foreign trials have shown that 100 mg twice daily is as effective as the 150-mg dose. Antacid should be given as needed for relief of pain.
  • Maintenance of Healing of Duodenal Ulcers: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) at bedtime.
  • Pathological Hypersecretory Conditions (such as Zollinger-Ellison syndrome): The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice a day. In some patients it may be necessary to administer Ranitidine 150-mg doses more frequently. Dosages should be adjusted to individual patient needs, and should continue as long as clinically indicated. Dosages up to 6 g/day have been employed in patients with severe disease.
  • Benign Gastric Ulcer: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice a day.
  • Maintenance of Healing of Gastric Ulcers: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) at bedtime.
  • GERD: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) twice a day. Erosive Esophagitis: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivalent to 150 mg of ranitidine) 4 times a day.
  • Maintenance of Healing of Erosive Esophagitis: The current recommended adult oral dosage is 150 mg or 10 mL of syrup (2 teaspoonfuls of syrup equivale to 150 mg of ranitidine) twice a day.
  • Pediatric Use: 
    • Treatment of Duodenal and Gastric Ulcers: The recommended oral dose for the treatment of active duodenal and gastric ulcers is 2 to 4 mg/kg twice daily to a maximum of 300 mg/day. This recommendation is derived from adult clinical studies and pharmacokinetic data in pediatric patients.
    • Maintenance of Healing of Duodenal and Gastric Ulcers: The recommended oral dose for the maintenance of healing of duodenal and gastric ulcers is 2 to 4 mg/kg once daily to a maximum of 150 mg/day.
    • Treatment of GERD and Erosive Esophagitis: Although limited data exist for these conditions in pediatric patients, published literature supports a dosage of 5 to 10 mg/kg per day, usually given as 2 divided doses.

Dosage Adjustment for Patients With Impaired Renal Function: Patients with renal impairment (creatinine clearance less than 50ml/min) will accumulate ranitidine, resulting in increased plasma concentrations. As a result, it is recommended that such patients take 150mg of ranitidine every night for 4 to 8 weeks. If necessary, the same dose should be used for maintenance treatment. If an ulcer does not heal following treatment, the usual dose of 150mg twice daily should be started, followed by maintenance treatment at 150mg at night if necessary.

How to use ranitidine effervescent tablets:

 

Side effects associated with the use of Ranitidine include-

  • headache
  • dizziness
  • diarrhea
  • constipation
  • asthenia
  • dry mouth
  • anorexia
  • myalgia
  • arthralgia
  • Symptomatic response to therapy with Ranitidine does not preclude the presence of gastric malignancy.
  • Since Ranitidine is excreted primarily by the kidney, dosage should be adjusted in patients with impaired renal function
  • Caution should be observed in patients with hepatic dysfunction since Ranitidine is metabolized in the liver. Rare reports suggest that Ranitidine may precipitate acute porphyric attacks in patients with acute porphyria. Ranitidine should therefore be avoided in patients with a history of acute porphyria.

Contraindication

Ranitidine is contraindicated for patients known to have hypersensitivity to the drug or any of the ingredients.

There is no known contraindications of Ranitidine in terms of food and drinks.

There is no known contraindications of Ranitidine in terms of health conditions.